Strategic Partnership Cygnus Technologies has entered a strategic partnership with Dyadic International to co-develop and offer Host Cell Protein quantification assays (HCP) for C1 cells, signaling potential for cross-sell of advanced bioprocess analytics and collaborator-led solutions.

Recent ELISA Offering The launch of the C1 HCP ELISA Assay presents an upsell opportunity to provide instrumented assay development, validation services, and ongoing quality assurance support to biomanufacturers adopting C1 cell platforms.

Awarded Innovation Award recognition for MockV RVLP Kit reinforces Cygnus Technologies’ reputation for novel assay kits, creating a doorway for expansion into turnkey analytical solutions and support contracts with large biopharma and contract manufacturers.

Maravai Ecosystem As part of Maravai LifeSciences, Cygnus sits within a broad ecosystem of assay and services, offering cross-pillar collaboration opportunities, channel leverage, and access to a larger customer base seeking integrated analytical solutions.

Market Positioning With a focus on host cell proteins and immune- and immunoassay capabilities, Cygnus can target biopharma manufacturers and CDMO partners needing robust HCP characterization, process development support, and regulatory-aligned quality systems across small to mid-size bioprocessing facilities.